TheLife Sciencesteam advised Royalty Pharma in connection with a synthetic royalty financing of up to $300 million to Zenas BioPharma, Inc. The funds will support Zenas BioPharma, Inc.'s obexelimab development program for IgG4-RD and other autoimmune diseases.
Royalty Pharmais the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.
The Goodwin team was led byJacqueline Mercier,Robert Crawford Jr.,Catherine Magazu,Elliot Horlick,Amine AssouadandJo-an Chen, and includedReid BagwellandZhe Yangon certain debt-related aspects. Patent and IP advice for the transaction was led byCarl MoralesandMaria Smith.Barry Bazianprovided bankruptcy and restructuring support for the transaction.
For more information on the deal, please read thepress release.